Angiographic Delivery of AD-MSC for Ulcerative Colitis
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Researchers are trying to determine the safety and feasibility of using an adipose derived
mesenchymal stem cell (MSC) to treat people with Ulcerative Colitis.